Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial
Evolocumab 可降低无已知显著动脉粥样硬化且患有糖尿病的患者首次发生重大心血管事件的风险:VESALIUS-CV 试验结果
期刊:Journal of the American Medical Association
影响因子:55
doi:10.1001/jama.2026.3277
Marston, Nicholas A; Bohula, Erin A; Bhatia, Ajay K; De Ferrari, Gaetano M; Leiter, Lawrence A; Nicolau, Jose C; Park, Jeong-Gun; Murphy, Sabina A; Walsh, Emileigh; Liu, Lyrica; Verma, Subodh; Sattar, Naveed; Nicholls, Stephen J; Lopez-Sendon, Jose; Gouni-Berthold, Ioanna; Tokgozoglu, Lale; Blankstein, Ron; Cyrille, Marcoli; da Silva Lima, Gabriel Paiva; Giugliano, Robert P; Sabatine, Marc S